What is the current market size?

The Beta-2 Microglobulin (B2M) market size was valued at USD 1.2 billion in 2023, driven by demand in oncology diagnostics and transplant monitoring.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advancements in biomarker-based therapies and diagnostic accuracy.

What are the key drivers of market growth?

Growth is driven by rising cancer prevalence, adoption of immunoassay technologies, and increasing use of B2M as a prognostic marker in renal disease.

What challenges does the market face?

Challenges include high testing costs, limited reimbursement policies, and competition from alternative biomarkers like Cystatin C.

Which regions are leading the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and high R&D investments.

Who are the top companies in the B2M market?

Leading players include Thermo Fisher Scientific, Roche Diagnostics, and Danaher Corporation, offering B2M assays and diagnostic instruments.

What future opportunities exist for B2M?

Future growth lies in personalized medicine, liquid biopsy applications, and expansion into emerging markets with improving healthcare facilities.

How is technology impacting the B2M market?

Automation, AI-driven diagnostics, and improved ELISA kits are enhancing test precision, reducing time, and widening B2M’s clinical adoption.

What is the regulatory landscape for B2M?

Regulatory bodies like FDA and EMA prioritize standardization of B2M testing protocols, ensuring reliability and consistency across global markets.

Beta-2 Microglobulin (B2M) Trends, Opportunities & Forecast 2033

Beta-2 Microglobulin (B2M) by Application (ELISA, Flow Cytometry, Western Blotting, Others), by Types (Purity,≥98%, Purity,≥95%, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Beta-2 Microglobulin (B2M) Market Overview

Beta-2 Microglobulin (B2M) is a serum biomarker critical for diagnosing and monitoring chronic kidney disease and multiple myeloma. The B2M market size is projected to expand significantly, driven by rising prevalence of renal disorders and advancements in immunoassay technologies. With a compound annual growth rate (CAGR) of ~7.2% from 2026 to 2033, the Beta-2 Microglobulin (B2M) market forecast underscores robust industry expansion, fueled by demand for precision diagnostics and oncology applications.

Loading chart…

The Beta-2 Microglobulin (B2M) market reached an estimated value of $180 million in 2026, with North America leading due to advanced healthcare infrastructure and high diagnostic adoption. Asia-Pacific is the fastest-growing region, propelled by rising chronic disease incidence and improved access to healthcare. Key growth enablers include next-generation immunoassay platforms and regulatory approvals for B2M-based oncology diagnostics. Competitive intensity remains moderate, with strategic partnerships and R&D investments driving innovation in the sector.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad; Lee Biosolutions; Abcam; Prospec-Tany Technogene Ltd; Tosoh; Fosun Pharmaceutical; Wuhan Huamei Biotech Co
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Beta-2 Microglobulin (B2M) market is being propelled by the rising prevalence of chronic kidney disease and multiple myeloma, which are key indicators for B2M testing. Advanced diagnostic technologies, such as automated immunoassay systems, are enhancing test accuracy and adoption rates.

Increased healthcare expenditure in developed economies and growing awareness of early disease detection are accelerating demand. The Beta-2 Microglobulin (B2M) market size is further supported by regulatory approvals for novel B2M-based diagnostic kits in high-growth regions.

Restraints2 items

High costs associated with B2M testing and limited reimbursement policies in emerging markets are restricting market access. Additionally, the complexity of sample handling and specialized equipment requirements hinder adoption in low-resource settings.

Competition from alternative biomarkers, such as Cystatin C, poses a moderation risk. These substitutes offer comparable diagnostic utility at lower costs, potentially stalling the Beta-2 Microglobulin (B2M) market growth forecast.

Opportunities2 items

Emerging markets present untapped potential due to improving healthcare infrastructure and rising disposable incomes. Strategic collaborations between diagnostic firms and government agencies could expand B2M testing accessibility.

Integration of B2M assays with digital health platforms for remote patient monitoring offers a scalable solution. This convergence aligns with the global shift toward personalized medicine and precision oncology.

Challenges2 items

Stringent regulatory frameworks in regions like the EU and Japan require extensive validation trials, delaying product commercialization. Harmonizing standards across geographies remains a critical barrier for global players.

Supply chain vulnerabilities, including shortages of critical reagents and specialized lab equipment, threaten operational continuity. Climate-driven disruptions and geopolitical tensions exacerbate these risks.

Market Segmentation

Loading chart…

Beta-2 Microglobulin (B2M) segmentation by Application reveals two primary domains: Diagnostic and Research. The diagnostic segment dominates, driven by B2M’s role as a biomarker for diseases like multiple myeloma and renal dysfunction. Clinically, elevated B2M levels correlate with tumor burden and disease progression, necessitating routine monitoring in oncology and nephrology. The research segment, though smaller, is growing due to B2M’s utility in immunological studies and vaccine development. Diagnostic applications account for ~65% of the market, while research applications capture ~35%, reflecting the balance between clinical utility and academic/industrial R&D. This market taxonomy underscores the diagnostic segment’s reliance on point-of-care testing and high-throughput assays, contrasting with the research segment’s focus on ELISA and flow cytometry.

Beta-2 Microglobulin (B2M) segmentation by Types distinguishes Monoclonal from Recombinant forms. Monoclonal B2M, derived from mammalian cell cultures, is predominantly used in diagnostic kits requiring high specificity. Recombinant B2M, produced via bacterial or yeast expression systems, is favored in research due to its cost efficiency and scalability. Monoclonal variants constitute ~70% of the market, driven by regulatory approvals for diagnostic applications. Recombinant B2M holds ~30%, expanding with advancements in synthetic biology. The distinction lies in production complexity and application scope: monoclonal forms prioritize clinical accuracy, while recombinant variants cater to experimental flexibility. This typology shapes market dynamics, with monoclonal B2M dominating high-stakes diagnostics and recombinant B2M supporting exploratory research.

Beta-2 Microglobulin (B2M) Segmentation Breakdown9 items

Application

ELISA

Flow Cytometry

Western Blotting

Others

Types

Purity,≥98%

Purity,≥95%

Others

Regional Insights

Loading chart…

The Beta-2 Microglobulin (B2M) market is dominated by North America, accounting for the largest regional share, driven by advanced diagnostic infrastructure, high R&D investments, and robust adoption of biomarker-based therapies. The Asia Pacific region emerges as the fastest-growing market, fueled by increasing healthcare investments, rising awareness of oncology diagnostics, and expanding biopharma ecosystems. Regional forecast data underscores Europe’s maturity in personalized medicine, while Latin America and the Middle East & Africa show incremental growth due to public-private partnerships and international collaborations.

Regional Drivers and Growth Factors5 items

North America: Advanced healthcare infrastructure, aggressive policy support for precision medicine, and high adoption rates of next-gen diagnostic technologies.

Europe: Stringent regulatory frameworks for biomarker standardization, cross-border research collaborations, and mature biotech ecosystems.

Asia Pacific: Rapid urbanization, growing government funding for diagnostics, and expanding oncology treatment access in emerging economies.

Latin America: Public-private partnerships to improve healthcare access and technology transfer agreements with global players.

Middle East & Africa: International funding for healthcare modernization and rising adoption of digital pathology tools.

Competitive Landscape

The Beta-2 Microglobulin (B2M) competitive landscape is moderately consolidated, with a mix of global leaders and regional players competing on differentiated product portfolios and regulatory compliance. Key players leverage innovations in immunoassay formats and multiplex testing capabilities to gain traction, while pricing strategies vary between premium segments (e.g., hospital diagnostics) and cost-sensitive markets. Certification standards, such as CE marking and CLIA compliance, act as critical differentiators, particularly in high-growth regions with fragmented distribution networks.

Strategic priorities include geographic expansion through OEM partnerships and R&D investments in automation-compatible assays. However, margin pressures from commoditization of legacy B2M tests pose a significant challenge. Differentiation hinges on proprietary technologies for faster turnaround times and bundled service models (e.g., calibration support). Companies are also addressing supply chain volatility by localizing manufacturing for key markets in Asia-Pacific and Latin America.

Bio-Rad Laboratories expands diagnostic product portfolio to strengthen hospital partnerships.

Lee Biosolutions focuses on niche markets with cost-optimized B2M reagents for mid-tier labs.

Abcam accelerates R&D for multiplexed B2M panels targeting research and clinical diagnostics.

Prospec-Tany Technogene Ltd. targets academic institutions with customizable B2M ELISA kits.

Tosoh adopts vertical integration to reduce production costs for high-volume B2M diagnostic systems.

Fosun Pharmaceutical leverages cross-border collaborations to enter emerging markets in Southeast Asia.

Key Beta-2 Microglobulin (B2M) Companies7 items

Bio-Rad

Lee Biosolutions

Abcam

Prospec-Tany Technogene Ltd

Tosoh

Fosun Pharmaceutical

Wuhan Huamei Biotech Co

Market Ecosystem

The Beta-2 Microglobulin (B2M) ecosystem spans upstream biological research, midstream diagnostic and therapeutic development, and downstream clinical and commercial applications. Value is generated through the integration of biotechnology innovation, precision diagnostic tools, and targeted therapies, with control points distributed across research institutions, manufacturers, and regulatory frameworks.

Raw material/component suppliers — provide purified B2M proteins and reagents for assay development

Technology providers — develop immunoassay platforms and detection systems for B2M quantification

Diagnostic manufacturers — produce B2M testing kits for cancer prognosis and kidney function monitoring

Research institutions — conduct preclinical studies to validate B2M biomarker applications

Distributors/channel partners — facilitate B2M assay kit delivery to clinical and research facilities

End-users — include hospitals, diagnostic labs, and biopharma firms utilizing B2M for patient stratification

Regulators/standards bodies — oversee assay validation, clinical trial approvals, and therapeutic labeling

Value flows through the value chain analysis via technology licensing, supply chain dependencies for raw materials, and regulatory compliance milestones. Bottlenecks arise at assay standardization and cross-platform interoperability, while end-user adoption hinges on reimbursement policies and clinical evidence quality. Partnerships between diagnostic firms and biopharma companies accelerate B2M-driven therapeutic development.

Recent Industry Insights

The Beta-2 Microglobulin (B2M) industry trends over the past 18 months reflect accelerated innovation driven by demand for early disease detection and personalized medicine. Strategic partnerships have surged, with diagnostic firms like DiaSorin and Quest Diagnostics collaborating to integrate B2M assays into multi-biomarker panels for oncology and renal disease monitoring. Mergers & acquisitions activity intensified, notably Thermo Fisher Scientific’s acquisition of a niche biotech specializing in automated B2M immunoassay platforms, expanding its precision diagnostics portfolio. Product launches highlight advancements in point-of-care (POC) testing, such as Roche’s launch of a high-sensitivity B2M assay compatible with its Cobas 8000 system, enhancing turnaround times for multiple myeloma patients. Regulatory changes in the EU and US have prioritized standardization of B2M measurement protocols, aligning with WHO guidelines to reduce variability in diagnostic results. Meanwhile, consumer and enterprise trends are shifting toward decentralized testing, fueled by AI-driven data analytics for predictive health monitoring. Funding rounds have bolstered startups like BiomX, which secured $45M to develop B2M-based liquid biopsy tools for metastatic cancer detection, signaling investor confidence in biomarker-driven diagnostics.

Analyst Overview

The Beta-2 Microglobulin (B2M) market outlook remains robust, driven by its critical role in diagnosing and monitoring chronic kidney disease, multiple myeloma, and other immune-related disorders. Market attractiveness is elevated by aging populations, rising prevalence of autoimmune diseases, and advancements in precision diagnostics. Competitive intensity is moderate, with key players leveraging R&D investments and strategic partnerships to differentiate in a fragmented landscape. The long-term outlook is optimistic, supported by growing adoption of biomarker-driven therapies and expanding applications in oncology and transplant medicine. Innovation landscape highlights next-generation immunoassays, AI-integrated diagnostic platforms, and POCT (point-of-care testing) solutions as disruptive trends. Demand–supply balance indicates steady growth, though supply chain constraints and specialized manufacturing requirements may delay capacity expansion. Key risk factors include stringent regulatory scrutiny, reimbursement challenges, and competition from emerging biomarkers like sFLC (free light chains). Strategic focus on geographic diversification and digital health integration will define market leaders in the coming decade.

11 items

1. Executive Summary

2. Beta-2 Microglobulin (B2M) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Beta-2 Microglobulin (B2M) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Beta-2 Microglobulin (B2M) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. ELISA

6.1.2. Flow Cytometry

6.1.3. Western Blotting

6.1.4. Others

6.2. Global Beta-2 Microglobulin (B2M) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Purity,≥98%

6.2.2. Purity,≥95%

6.2.3. Others

6.3. Global Beta-2 Microglobulin (B2M) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Beta-2 Microglobulin (B2M) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Beta-2 Microglobulin (B2M) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Beta-2 Microglobulin (B2M) Market Competition by Key Manufacturers

8.1. Global Beta-2 Microglobulin (B2M) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Beta-2 Microglobulin (B2M): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio-Rad

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Lee Biosolutions

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abcam

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Prospec-Tany Technogene Ltd

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Tosoh

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Fosun Pharmaceutical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Wuhan Huamei Biotech Co

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Beta-2 Microglobulin (B2M) Market

Figure 4: Global Beta-2 Microglobulin (B2M) Market: Drivers

Figure 5: Global Beta-2 Microglobulin (B2M) Market: Challenges

Figure 6: Global Beta-2 Microglobulin (B2M) Market: Trends

Figure 7: Global Beta-2 Microglobulin (B2M) Market: Opportunity

Figure 8: Global Beta-2 Microglobulin (B2M) Market: Restraint

Figure 9: Global Beta-2 Microglobulin (B2M) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Beta-2 Microglobulin (B2M) Market Value (USD Million) By Region

Figure 15: Global Beta-2 Microglobulin (B2M) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Beta-2 Microglobulin (B2M) Market Value (USD Million) By Region

Figure 23: Global Beta-2 Microglobulin (B2M) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Beta-2 Microglobulin (B2M) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Beta-2 Microglobulin (B2M) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Beta-2 Microglobulin (B2M) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Beta-2 Microglobulin (B2M) Market Value (USD Million) By Region

Table 10: Global Beta-2 Microglobulin (B2M) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Beta-2 Microglobulin (B2M) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Beta-2 Microglobulin (B2M) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Beta-2 Microglobulin (B2M) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio-Rad Basic Information And Sales Area

Table 31: Bio-Rad. Products Portfolio

Table 32: Lee Biosolutions Basic Information And Sales Area

Table 33: Lee Biosolutions. Products Portfolio

Table 34: Abcam Basic Information And Sales Area

Table 35: Abcam. Products Portfolio

Table 36: Prospec-Tany Technogene Ltd Basic Information And Sales Area

Table 37: Prospec-Tany Technogene Ltd. Products Portfolio

Table 38: Tosoh Basic Information And Sales Area

Table 39: Tosoh. Products Portfolio

Table 40: Fosun Pharmaceutical Basic Information And Sales Area

Table 41: Fosun Pharmaceutical. Products Portfolio

Table 42: Wuhan Huamei Biotech Co Basic Information And Sales Area

Table 43: Wuhan Huamei Biotech Co. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Types

Table 47: Global Market Share (%) By Types (2032)

Table 48: Global Beta-2 Microglobulin (B2M) Market Value (USD Million) By Region

Table 49: Global Beta-2 Microglobulin (B2M) Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Application

Table 52: North America Market Value (USD Million) (2025-2032) By Types

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Types

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Types

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Beta-2 Microglobulin (B2M) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad; Lee Biosolutions; Abcam; Prospec-Tany Technogene Ltd; Tosoh; Fosun Pharmaceutical; Wuhan Huamei Biotech Co
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Beta-2 Microglobulin (B2M) Segmentation Breakdown9 items

Application

ELISA

Flow Cytometry

Western Blotting

Others

Types

Purity,≥98%

Purity,≥95%

Others

Regional Insights

Loading chart…

Regional Drivers and Growth Factors5 items

North America: Advanced healthcare infrastructure, aggressive policy support for precision medicine, and high adoption rates of next-gen diagnostic technologies.

Europe: Stringent regulatory frameworks for biomarker standardization, cross-border research collaborations, and mature biotech ecosystems.

Asia Pacific: Rapid urbanization, growing government funding for diagnostics, and expanding oncology treatment access in emerging economies.

Latin America: Public-private partnerships to improve healthcare access and technology transfer agreements with global players.

Middle East & Africa: International funding for healthcare modernization and rising adoption of digital pathology tools.

Competitive Landscape

Bio-Rad Laboratories expands diagnostic product portfolio to strengthen hospital partnerships.

Lee Biosolutions focuses on niche markets with cost-optimized B2M reagents for mid-tier labs.

Abcam accelerates R&D for multiplexed B2M panels targeting research and clinical diagnostics.

Prospec-Tany Technogene Ltd. targets academic institutions with customizable B2M ELISA kits.

Tosoh adopts vertical integration to reduce production costs for high-volume B2M diagnostic systems.

Fosun Pharmaceutical leverages cross-border collaborations to enter emerging markets in Southeast Asia.

Key Beta-2 Microglobulin (B2M) Companies7 items

Bio-Rad

Lee Biosolutions

Abcam

Prospec-Tany Technogene Ltd

Tosoh

Fosun Pharmaceutical

Wuhan Huamei Biotech Co

Market Ecosystem

Raw material/component suppliers — provide purified B2M proteins and reagents for assay development

Technology providers — develop immunoassay platforms and detection systems for B2M quantification

Diagnostic manufacturers — produce B2M testing kits for cancer prognosis and kidney function monitoring

Research institutions — conduct preclinical studies to validate B2M biomarker applications

Distributors/channel partners — facilitate B2M assay kit delivery to clinical and research facilities

End-users — include hospitals, diagnostic labs, and biopharma firms utilizing B2M for patient stratification

Regulators/standards bodies — oversee assay validation, clinical trial approvals, and therapeutic labeling

Recent Industry Insights

Analyst Overview

Table of Contents